1 / 37

Toxicity of stavudine- and nevirapine-containing antiretroviral treatment regimens:

Toxicity of stavudine- and nevirapine-containing antiretroviral treatment regimens:. incidence and risk factors after 3 years in a large cohort in Rwanda. Johan van Griensven. Background (1). 90% of ART regimens in low-income countries use fixed dose combination of: Stavudine (d4T)

latif
Download Presentation

Toxicity of stavudine- and nevirapine-containing antiretroviral treatment regimens:

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Toxicity of stavudine- and nevirapine-containing antiretroviral treatment regimens: incidence and risk factors after 3 years in a large cohort in Rwanda Johan van Griensven

  2. Background (1) • 90% of ART regimens in low-income countries use fixed dose combination of: • Stavudine (d4T) • Lamivudine (3TC) • Nevirapine (NVP)

  3. Background (2) • Long-term toxicity well-described in high-income countries • Stavudine (d4T) • Abandoned for reasons of toxicity • First choice in low-income countries • Nevirapine (NVP) • significant morbidity/mortality • contra-indicated for higher CD4 counts (> 250)

  4. Objectives • Assess incidence, timing and risk factors of toxicity with D4T and NVP in Rwanda

  5. ART program in 2 urban health centers, Kigali 3,417 patients started on ART by Dec 07 Open cohort: 90% in care by 2 years of ART Diagnostic tools available ARV KMK ARV KNN Methods (1): Setting

  6. Methods (2) • Study population • N= 2,970 • 2,667 started stavudine-based regimen (90.6%) • 2,694 started nevirapine-based regimen (89.6%) • Side-effects/toxicity • WHO definitions (grading) • Symptomatic hyperlactatemia/lactic acidosis • Lipoatrophy

  7. Methods (3) • Side-effects/toxicity • WHO definitions (grading) • Symptomatic hyperlactatemia/lactic acidosis • Lipoatrophy • Probabilities of ‘time to first severe toxicity’ requiring treatment change (KM) • related to NVP and D4T • A risk factor analysis • multivariate Cox proportional hazards modelling

  8. Results (1): baseline characteristics • WHO stage • stage I (6.5%) • stage II (28.4%) • stage III (56.6%) • stage IV (8.5%) • Baseline CD4 count: 162 cells/µL • Median time on ART: 1.5 years

  9. Results (2): NVP toxicity • Severe toxicity (drug-substitution): 6.4% (170) • Rash: 4.9% (130) • Hepatitis: 1.5% (40) • Early toxicity • Within first 6 months of treatment for 90 % • Not clearly different from what reported in high and low-income countries

  10. Results (3): Risk factors • Skin toxicity: non-significant • Hepatotoxicity • BMI ≤20 kg/m2 • Abnormal baseline liver tests • No association with baseline CD4 count and sex

  11. Results (4): Risk factors for severe toxicity • Similar findings from several other African studies • Contrasts with findings from high income countries • Female sex • CD4 count > 250 cells/µL

  12. Results (5): Stavudine toxicity • Neuropathy: 7.6% (206) • Lactic acidosis (SH/LA): 3.2% (85) • Lipoatrophy (body fat changes): 6.7% (180) • Total: 16.6% (448) • Similar findings from other African countries

  13. Results (6): Stavudine toxicity

  14. Results (7): Stavudine toxicity

  15. Results (8): Lipoatrophy

  16. Results (9): Risk factors

  17. Conclusion (1) • Toxicity of NVP similar to high-income countries • Different risk factors? • Risk factors different ? • Different from rich countries • Allergy vs toxicity ? • Implications for ART initiation and PMTCT protocols • Safe to give NVP when high baseline CD4 counts ?

  18. Conclusion (2) • D4T has severe, long-term toxicity • Main concern is • lactic acidosis: mortality • Lipoatrophhy: acceptance and adherence ?

  19. Implications for MSF? • Risk factors could help identify patients at higher risk of drug toxicity • Develop diagnostic and treatment paths with few diagnostic tools to ensure pro-active management • ART programs need alternatives • tenofovir (TDF) or abacavir (ABV) • at present prohibitively expensive

  20. Acknowledgements • Health Centres Kinyinya and Kimironko • MSF team Rwanda (2002-2007) • Ministry of Health Rwanda

  21. 226 $/machine 2.3 $/test Interfering factors: Exercise Hydratation Nutrition ? Infections malaria, TB ? Asymptomatic hyperlactatemia Action threshold ? Clinical evaluation Diagnostic tool: Accutrend

  22. NVP-related toxicity

  23. D4T-related toxicity

  24. Incidence of neuropathy

  25. Hyperlactatemia/lactic acidosis • Rwanda • Substitution for 3.2 % of patients on d4T • IR 20/1000 patient years • 6 % by 3 years on ARV • South-Africa • Soweto: 30/1000 patient years (CID, 2007) • Durban: 30/1000 patient years • Cape Town: 19/1000 patient years • Botswana (CID, 2007), Uganda (JAIDS 2007)

  26. Acidose lactique/hyperlactatemie • South-Africa (Clin Infect Dis, 2007) – Soweto • Symptomatic hyperlactatemia: • 20/1000 py • Mortality 0 % • Lactic acidosis: • 10/1000 py • Mortality 30 % • South-Africa – Durban • 37/1000 py

  27. Definition • Technical investigations: CT/DEXA/MRI (Golden Standard) • Clinical • “Lipodystrophy Case Definition Study” Questionnaire • Validated vs “golden standard” • Anthropometrics • Rwanda: screening for long-term side-effects integrated in routine care

  28. 1. Evaluation par le patient Au visage 0 - + un peu □ moyen □ beaucoup □ Au cou 0 - + un peu □ moyen □ beaucoup □ Au seins 0 - + un peu □ moyen □ beaucoup □ Au ventre 0 - + un peu □ moyen □ beaucoup □ Aux fesses 0 - + un peu □ moyen □ beaucoup □ Aux bras 0 - + un peu □ moyen □ beaucoup □ Au jambes 0 - + un peu □ moyen □ beaucoup □ 2. Evaluation par l’infirmière Au visage 0 - + un peu □ moyen □ beaucoup □ Au cou 0 - + un peu □ moyen □ beaucoup □ Au seins 0 - + un peu □ moyen □ beaucoup □ Au ventre 0 - + un peu □ moyen □ beaucoup □ Aux fesses 0 - + un peu □ moyen □ beaucoup □ Aux bras 0 - + un peu □ moyen □ beaucoup □ Au jambes 0 - + un peu □ moyen □ beaucoup □ Depuis quand ces changements ont-ils commencé ?  .….jours/semaine(s)/mois/année(s)

  29. Symptômes associés (arguments pour acidose lactique) ? Depuis quand ? Paresthésie non □ un peu □ moyen □ beaucoup □ …..jours/sem/mois/années Nausée non □ un peu □ moyen □ beaucoup □ …..jours/sem/mois/années Vomissement non □ un peu □ moyen □ beaucoup □ …..jours/sem/mois/années Diarrhée non □ un peu □ moyen □ beaucoup □ …..jours/sem/mois/années Inappétence non □ un peu □ moyen □ beaucoup □ …..jours/sem/mois/années Douleur non □ un peu □ moyen □ beaucoup □ …..jours/sem/mois/années abdominal Gonflement non □ un peu □ moyen □ beaucoup □ …..jours/sem/mois/années abdominal Dyspnée non □ un peu □ moyen □ beaucoup □ …..jours/sem/mois/années repos □ effort □ Fatigue non □ un peu □ moyen □ beaucoup □ …..jours/sem/mois/années Perte de poids …. kg en ….. jours/sem/mois Augmentation de poids …. kg en ….. jours/sem/mois Autres symptômes …………………………………………… Quand est-ce que ces symptôms ont-ils commencé ? …..jours/sem/mois/années

  30. Frequency of lipodystrophie • Cross-sectional evaluation (> 1 an sous ARV, n=409) • Lipodystrophy: 34 % • Isolated lipoatrophy: 10 % • Isolated lipohypertrophy: 5 % • Mixed presentation: 19 % • Moderate/severe > 60-70 % • “Body changes disturbing” > 50 % • Cohort on d4T (severe lipoatrophy): • Substitution of lipoatrophie for 6.7 % • Incidence of 43/1000 py • 20 % by 3 years on ART

  31. Incidence of La in Africa ? • Until recently rarely reported • First report coming from MSF Rwanda • CROI, Feb 2006 • South-Africa • Prospective cohort study (George) • 43 % lipodystrophy by 2 years onARV • Cape Town, 2007 • 9 % substituted d4T for La by 3 ans of ARV • Implementers meeting (2006), Durban: • Substitution for lipoatrophy: 73/1000 py • Rwanda (KIST): • Prevalence of 70 % by 3 years

  32. Toxicity of ARVs (South-Afr)

  33. Toxicity of ARVs (South-Afr)

More Related